Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Publication
, Journal Article
Kumar, SK; Callander, NS; Adekola, K; Anderson, LD; Baljevic, M; Campagnaro, E; Castillo, JJ; Costello, C; D'Angelo, C; Devarakonda, S; Htut, M ...
Published in: J Natl Compr Canc Netw
January 2023
Primary systemic light chain amyloidosis (SLCA) is characterized by production of light chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The therapy for SLCA is directed to recovering the function of the affected organs by targeting the abnormal plasma cell clone and slowing deposition of amyloid fibrils. The NCCN Guidelines for SLCA provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated SLCA.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2023
Volume
21
Issue
1
Start / End Page
67 / 81
Location
United States
Related Subject Headings
- Plasma Cells
- Oncology & Carcinogenesis
- Humans
- Amyloidosis
- Amyloid
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Campagnaro, E., … Kumar, R. (2023). Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 21(1), 67–81. https://doi.org/10.6004/jnccn.2023.0001
Kumar, Shaji K., Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, et al. “Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 21, no. 1 (January 2023): 67–81. https://doi.org/10.6004/jnccn.2023.0001.
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Campagnaro E, et al. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Jan;21(1):67–81.
Kumar, Shaji K., et al. “Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 21, no. 1, Jan. 2023, pp. 67–81. Pubmed, doi:10.6004/jnccn.2023.0001.
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D’Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Sborov D, Valent J, Berardi R, Kumar R. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Jan;21(1):67–81.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2023
Volume
21
Issue
1
Start / End Page
67 / 81
Location
United States
Related Subject Headings
- Plasma Cells
- Oncology & Carcinogenesis
- Humans
- Amyloidosis
- Amyloid
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis